Giant Cell Arteritis
94
20
27
42
Key Insights
Highlights
Success Rate
81% trial completion
Published Results
14 trials with published results (15%)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
10.6%
10 terminated out of 94 trials
80.8%
-5.7% vs benchmark
20%
19 trials in Phase 3/4
33%
14 of 42 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 42 completed trials
Clinical Trials (94)
TocilizuMab discontinuAtion in GIant Cell Arteritis
A Clinical Trial to Investigate 18F-AzaFol in the Diagnosis of Large Vessel Vasculitis
Risk of Diabetes Mellitus in Patients With Giant Cell Arthritis and Polymyalgia Rheumatica.
MEthotrexate Versus TOcilizumab for Treatment of GIant Cell Arteritis: a Multicenter, Randomized, Controlled Trial
Early Temporal Dynamics of Optic Nerve Sheath Diameter After Therapy in GCA
Giant Cell Arteritis and Anakinra Trial
Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Intravenous Secukinumab in Patients With GCA or PMR
Studies of the Natural History, Pathogenesis, and Outcome of Idiopathic Systemic Vasculitis
Association of Ultrasonographic Temporal Artery Lesions and Relapse in Patients With Giant Cell Arteritis
Effect of Supplemental Hydrocortisone During Stress in Prednisolone-induced Adrenal Insufficiency
Efficacy and Safety of Secukinumab in Patients With New Onset of Giant Cell Arteritis Who Are in Clinical Remission
Rheumatology Patient Registry and Biorepository
Evaluation of PET/CT of Cephalic Arteries for the Diagnosis of Giant Cell Arteritis
Abatacept for the Treatment of Giant Cell Arteritis
Low Dose Naltrexone to Improve Physical Health in Patients With Vasculitis
One-Time DNA Study for Vasculitis
VCRC Tissue Repository
Impact of the Spatial Resolution of Several Contrast-enhanced 3D T1-WI Sequences When Diagnosing Giant Cell Arteritis (GCA)
Giant Cell Arteritis - Ways to Precision Medicine
Improved Diagnostics and Monitoring of Polymyalgia Rheumatica